LIXTE Biotechnology Enters Exclusive Immune Oncology Patent License Agreement With NINDS & NCI
LIXTE Biotechnology Holdings, Inc. recently announced the signing of an exclusive patent license agreement with the National Institute of Neurological Disorders and Stroke (NINDS) and National Cancer Institute (NCI), each a component of the National Institute of Health (NIH).
Under the terms of the license agreement, LIXTE has licensed exclusively NIH’s intellectual property rights claimed for a Cooperative Research and Development Agreement (CRADA) subject invention co-developed with Lixte, and the licensed field of use, which focuses on promoting anti-cancer activity alone, or in combination with standard anti-cancer drugs. The scope of this clinical research extends to checkpoint inhibitors, immunotherapy, and radiation for the treatment of cancer.
“This strategic collaboration marks a significant milestone in advancing LIXTE’s mission to advance cancer therapy by developing its first-in-class lead clinical PP2A inhibitor, LB-100, as a potentiator of cancer immunotherapy,” said Bas van der Baan, Chief Executive Officer of LIXTE. “We are excited to embark on this journey as it opens up new avenues for advancing our commitment to developing effective and targeted anti-cancer therapies. The agreement reinforces our dedication to pioneering research and delivering innovative solutions to patients battling cancer,” he added.
The collaboration harnesses the synergies of LIXTE’s innovative compound, LB-100, and NINDS’s and NCI’s cutting-edge research capabilities. The licensed patent rights provide LIXTE with a unique opportunity to explore and develop novel combination therapies that can potentially transform the landscape of cancer treatment.
LIXTE recently announced the entry of the first patient into a Phase 1b/2 clinical trial to assess whether adding LIXTE’s LB-100 to GSK’s programmed death receptor-1 (PD-1)-blocking monoclonal antibody, dostarlimab-gxly, has the ability to enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma (OCCC). Another Phase 1b clinical trial in small cell lung cancer combining LB-100 with Roche’s atezolizumab and chemotherapy is also actively recruiting. The Company intends to develop additional clinical trials with LB-100 to enhance the efficacy of chemotherapy and immunotherapy.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com), LB-100 has the potential to significantly improve outcomes for patients undergoing various chemotherapies or immunotherapies. LIXTE’s new approach has no known competitors and is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are in progress.
Total Page Views: 559
